Trial Profile
A Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2018
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 30 Oct 2018 Planned End Date changed from 1 Dec 2020 to 3 Dec 2020.
- 30 Oct 2018 Planned primary completion date changed from 1 Dec 2020 to 3 Dec 2020.
- 30 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 25 Sep 2018.